Aligos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Aligos Therapeutics, Inc. on June 17, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol ALGS. The record date for the meeting was April 21, 2021, with 35,055,445 shares of voting common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Lawrence M. Blatt, Ph.D.: 21,653,290 votes For; 848,627 votes Withheld; 947,506 Broker Non-Votes.
- James Scopa: 22,499,729 votes For; 2,188 votes Withheld; 947,506 Broker Non-Votes.
- Proposal 2: Ratification of Auditors
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 23,449,333; Votes Against: 90; Abstentions: 0.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the stockholder vote.
Key Facts for Investor Verification
- Both Class I director nominees (Lawrence M. Blatt, Ph.D. and James Scopa) were elected.
- Ernst & Young LLP was overwhelmingly ratified as the independent auditor.
- Broker non-votes were recorded for the director election but not for the auditor ratification.
- The report contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.